News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Oncolytics Biotech Inc. Announces 2005 Third Quarter Results


Posted on: 10/26/2005

Oncolytics Biotech Inc. Announces 2005 Third Quarter Results

CALGARY, Oct. 26 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three and nine month periods ending September 30, 2005.
Recent Highlights

  • Commenced patient enrolment in a combination REOLYSIN(R)/radiation clinical trial in the U.K.
  • Commenced patient enrolment in a Phase I systemic administration clinical trial in the U.S.
  • Strengthened the management team with the appointment of Karl Mettinger, M.D., Ph.D. to the position of Chief Medical Officer
  • Secured a 2nd European patent entitled "Method of Producing Infectious Reovirus"
  • Secured a first Canadian patent entitled "The use of ribozymes in the detection of adventitious agents"
  • Subsequent to the quarter end, announced that Oncolytics collaborators would make two presentations at the AACR-NCI-EORTC Conference in November 2005
  • Subsequent to the quarter end, announced that patient treatment has been concluded in its Phase I recurrent malignant gliomas trial in Canada
  • Subsequent to the quarter end, announced the issuance of two additional Canadian patents covering methods and treatment of various cancers and other cellular proliferative disorders.

"The Company made progress in the quarter in further advancing the expanding clinical program for REOLYSIN(R) and strengthening its international intellectual property portfolio," said Dr. Brad Thompson, President and CEO of Oncolytics. "We were also pleased to have appointed Dr. Mettinger to our management team, who will play an important role in the further development and implementation of a clinical trial program that best supports a registration path for REOLYSIN(R)."


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740